Humanigen Inc (fka HGENQ)

[MWM]

During her research, Lynn learned that a majority of deaths associated with COVID-19 are caused by inflammation from cytokine (sy-toe-kine) storm, an over-reaction of the immune system (or hyper-response). As many as 89% of hospitalized COVID-19 patients are at risk of cytokine storm, a leading cause of COVID-19 disease progression, including death. But there's good news: hospitals across the U.S. are seeking patients to enroll in a Phase 3 trial evaluating an investigational treatment called lenzilumab(TM) designed specifically to target this storm.

Lynn found out that a nearby hospital in Livingston, New Jersey was one of the hospitals enrolling patients in the Phase 3 lenzilumab study, and that the duration of treatment for lenzilumab is only 24 hours.

When she learned that the goal of the trial is to determine if lenzilumab can help hospitalized COVID-19 patients recover faster, she called the trial director at that hospital, Dr. Anup Patel, to see if Marc could participate.

https://www.augustachronicle.com/ZZ/sponsored/20201019/recovered-covid-19-patient-urges-others-to-participate-in-clinical-trials